ArkeaBio Raises $15M Series A2 to Move Its Methane Vaccine Toward Market

ArkeaBio has raised a $15 million Series A2 to move its livestock methane vaccine toward regulatory approval and first commercial sales. AgriZeroNZ led the round, with Breakthrough Energy Ventures participating.

The financing comes with a tighter operating plan. Chief executive Frank Wooten told AgFunderNews that ArkeaBio reduced headcount by about one-third while narrowing its focus to New Zealand, its first product and initial revenue.

ArkeaBio Series A2 at a glance

Why a methane vaccine is different

Cattle and other ruminants produce methane as microbes digest feed in the rumen. Many emissions-reduction products are feed additives that must be delivered repeatedly and work best in controlled feeding systems. ArkeaBio is trying to use a familiar animal-health workflow instead: vaccination.

The company’s approach is intended to prompt an animal’s immune system to produce antibodies against methane-forming microbes. If the effect is durable, producers could administer a vaccine through existing veterinary and livestock-handling channels rather than adding a product to every meal.

That is the commercial advantage ArkeaBio must prove. A vaccine that is convenient but reduces too little methane, varies across herds or costs too much per tonne avoided will struggle against feed additives, selective breeding, microbiome tools and other interventions.

What the financing must deliver

ArkeaBio is targeting regulatory approval in New Zealand next year and commercial sales in 2028. Management currently expects the first product to reduce methane by about 10% to 15%, with later versions intended to improve efficacy. Those numbers and dates are company projections, not independently validated commercial results.

The workforce reduction is therefore an important part of the financing story. This is not an expansion round funding every research path. It is a runway round designed to reach a specific value-changing milestone: a regulated product with initial revenue in a market where agricultural methane reduction has policy and industry support.

ArkeaBio previously announced a $26.5 million Series A in 2024 led by Breakthrough Energy Ventures, followed by additional AgriZeroNZ backing. The new Series A2 deepens the same strategic investor relationships rather than introducing a broad new syndicate.

The diligence questions

Investors and agricultural buyers will need evidence on:

• repeatable methane reduction across animals, diets and farm systems;
• duration of protection and required dosing frequency;
• animal health and productivity effects;
• regulatory approval and measurement rules for emissions claims; and
• cost per tonne of methane or carbon-dioxide equivalent avoided.

New Zealand is a logical first market because livestock emissions are economically and politically material, and AgriZeroNZ was created specifically to back emissions-reduction tools for agriculture. It is also a demanding proving ground: farmers need the product to fit normal operations and produce an outcome that can be measured credibly.

Bottom line

ArkeaBio’s $15 million Series A2 is a confirmed climate-biotech financing with a clear milestone attached. The compelling part is not the phrase “methane vaccine” on its own. It is whether the company can turn an experimentally interesting mechanism into a regulated product that farmers can administer economically at scale.

_Funding, efficacy targets and timelines are presented for research and educational purposes. Company projections require independent validation._